Compass Therapeutics (CMPX) Competitors $3.97 +0.08 (+2.06%) Closing price 04:00 PM EasternExtended Trading$3.96 -0.01 (-0.13%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. DYN, BHC, SRPT, ETNB, MESO, OCUL, ANIP, VERA, COGT, and STOKShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Dyne Therapeutics (DYN), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), 89BIO (ETNB), Mesoblast (MESO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Cogent Biosciences (COGT), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors Dyne Therapeutics Bausch Health Cos Sarepta Therapeutics 89BIO Mesoblast Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Cogent Biosciences Stoke Therapeutics Compass Therapeutics (NASDAQ:CMPX) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Do insiders and institutionals have more ownership in CMPX or DYN? 68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, CMPX or DYN? Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Does the media favor CMPX or DYN? In the previous week, Compass Therapeutics had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 4 mentions for Compass Therapeutics and 0 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.77 beat Compass Therapeutics' score of 0.43 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Compass Therapeutics Neutral Dyne Therapeutics Very Positive Do analysts rate CMPX or DYN? Compass Therapeutics currently has a consensus price target of $13.10, suggesting a potential upside of 229.97%. Dyne Therapeutics has a consensus price target of $34.07, suggesting a potential upside of 98.99%. Given Compass Therapeutics' higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Dyne Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 4 Strong Buy rating(s) 2.94 Which has preferable valuation & earnings, CMPX or DYN? Compass Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass TherapeuticsN/AN/A-$49.38M-$0.45-8.82Dyne TherapeuticsN/AN/A-$317.42M-$3.86-4.44 Is CMPX or DYN more profitable? Compass Therapeutics' return on equity of -53.11% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -53.11% -46.14% Dyne Therapeutics N/A -64.12%-56.75% SummaryCompass Therapeutics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$548.98M$3.42B$6.15B$10.77BDividend YieldN/A2.26%5.71%4.83%P/E Ratio-8.8223.3129.7228.55Price / SalesN/A271.94499.21189.70Price / CashN/A45.1236.6160.67Price / Book4.3610.4012.016.61Net Income-$49.38M-$52.62M$3.32B$276.82M7 Day Performance-6.81%2.14%1.54%1.96%1 Month Performance13.75%10.90%6.10%2.53%1 Year Performance125.57%13.64%61.10%32.80% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics2.4453 of 5 stars$3.97+2.1%$13.10+230.0%+117.3%$548.98MN/A-8.8220Analyst ForecastGap DownDYNDyne Therapeutics3.0963 of 5 stars$17.08+4.3%$34.07+99.5%-49.0%$2.33BN/A-4.42100Positive NewsAnalyst ForecastGap UpBHCBausch Health Cos4.6666 of 5 stars$6.32+4.5%$9.00+42.4%-21.0%$2.24B$9.63B24.3220,700Positive NewsUpcoming EarningsAnalyst ForecastSRPTSarepta Therapeutics4.5849 of 5 stars$23.05+2.4%$34.42+49.3%-83.1%$2.20B$1.90B-26.491,372Analyst ForecastETNB89BIO2.8725 of 5 stars$14.80+0.3%$25.81+74.4%+89.5%$2.19BN/A-4.1040Analyst ForecastShort Interest ↓MESOMesoblast1.9919 of 5 stars$17.65+3.4%$24.00+36.0%+82.5%$2.18B$17.20M0.0080OCULOcular Therapeutix4.283 of 5 stars$12.18+2.9%$22.63+85.8%+5.3%$2.06B$63.72M-9.52230ANIPANI Pharmaceuticals3.6948 of 5 stars$95.12+0.3%$99.14+4.2%+60.7%$2.06B$614.38M-123.53600Analyst UpgradeVERAVera Therapeutics2.8921 of 5 stars$30.20-3.3%$61.50+103.6%-29.3%$1.99BN/A-8.4440Analyst ForecastCOGTCogent Biosciences2.3621 of 5 stars$16.22-1.0%$19.67+21.2%+20.7%$1.87BN/A-9.1180Analyst ForecastGap UpSTOKStoke Therapeutics3.1299 of 5 stars$34.65+3.3%$30.83-11.0%+162.8%$1.84B$36.56M40.77100 Related Companies and Tools Related Companies DYN Alternatives BHC Alternatives SRPT Alternatives ETNB Alternatives MESO Alternatives OCUL Alternatives ANIP Alternatives VERA Alternatives COGT Alternatives STOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
